Overview

Thalidomide in Treating Patients With Thyroid Cancer

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have thyroid cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Kenneth Ain
University of Kentucky
Collaborator:
National Cancer Institute (NCI)
Treatments:
Thalidomide